Literature DB >> 28847676

Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians.

Atul Mehta1, Nadia Belmatoug2, Bruno Bembi3, Patrick Deegan4, Deborah Elstein5, Özlem Göker-Alpan6, Elena Lukina7, Eugen Mengel8, Kimitoshi Nakamura9, Gregory M Pastores10, Jordi Pérez-López11, Ida Schwartz12, Christine Serratrice13, Jeffrey Szer14, Ari Zimran15, Maja Di Rocco16, Zoya Panahloo17, David J Kuter18, Derralynn Hughes19.   

Abstract

Gaucher disease (GD) is a rare hereditary disorder caused by a deficiency of the lysosomal enzyme β-glucocerebrosidase. Diagnosis is challenging owing to a wide variability in clinical manifestations and severity of symptoms. Many patients may experience marked delays in obtaining a definitive diagnosis. The two surveys reported herein aimed to explore the patient journey to diagnosis of GD from the perspectives of Gaucher expert physicians and patients. Findings from the surveys revealed that many patients experienced diagnostic delays and misdiagnoses, with nearly 1 in 6 patients stating that they were not diagnosed with GD for 7years or more after first consulting a doctor. Physicians and patients both reported multiple referrals to different specialties before a diagnosis of GD was obtained, with primary care, haematology/haematology-oncology and paediatrics the main specialties to which patients first presented. Splenomegaly, thrombocytopenia, anaemia and bone pain were reported as the most common medical problems at first presentation in both surveys. These findings support a clear need for straightforward and easy-to-follow guidance designed to assist non-specialists to identify earlier patients who are at risk of GD.
Copyright © 2017 The Authors and Shire HGT Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Delayed diagnosis; Diagnosis; Gaucher disease; Patient survey; Physician survey

Mesh:

Year:  2017        PMID: 28847676     DOI: 10.1016/j.ymgme.2017.08.002

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  12 in total

1.  MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association.

Authors:  Neal J Weinreb; Pramod K Mistry; Barry E Rosenbloom; Madhav V Dhodapkar
Journal:  Blood       Date:  2018-04-12       Impact factor: 22.113

2.  Recent advances in the diagnosis and management of Gaucher disease.

Authors:  Sam E Gary; Emory Ryan; Alta M Steward; Ellen Sidransky
Journal:  Expert Rev Endocrinol Metab       Date:  2018-03-12

Review 3.  A patient with Gaucher disease and plasma cell dyscrasia: bidirectional impact.

Authors:  Ari Zimran; Rosa Ruchlemer; Shoshana Revel-Vilk
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Gaucher disease in North Macedonia: Unexpected prevalence of the N370S GBA1 allele with attenuated disease expression.

Authors:  Nevenka Ridova; Sanja Trajkova; Biljana Chonevska; Zlate Stojanoski; Martin Ivanovski; Marija Popova-Labachevska; Simona Stojanovska-Jakimovska; Venko Filipche; Aspazija Sofijanova; Irina Panovska-Stavridis
Journal:  Mol Genet Metab Rep       Date:  2022-07-08

5.  Pitfalls in the diagnosis of Gaucher disease in Iraq: A diagnostic experience from a developing country.

Authors:  Rabab Farhan Thejeal; Saja Baheer Abdul Wahhab; Nebal Waill Saadi
Journal:  Pak J Med Sci       Date:  2021 May-Jun       Impact factor: 1.088

6.  Sex-Specific Patient Journeys in Early Parkinson's Disease in the Netherlands.

Authors:  Floris Pieter Vlaanderen; Yvonne de Man; Jesse H Krijthe; Marit A C Tanke; A S Groenewoud; Patrick P T Jeurissen; Sabine Oertelt-Prigione; Marten Munneke; Bastiaan R Bloem; Marjan J Meinders
Journal:  Front Neurol       Date:  2019-07-30       Impact factor: 4.003

7.  The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland.

Authors:  Markku J Savolainen; Antti Karlsson; Samppa Rohkimainen; Iiro Toppila; Mariann I Lassenius; Carlos Vaca Falconi; Kristiina Uusi-Rauva; Kaisa Elomaa
Journal:  Mol Genet Metab Rep       Date:  2021-02-09

8.  Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia.

Authors:  Irene Motta; Dario Consonni; Marina Stroppiano; Christian Benedetto; Elena Cassinerio; Barbara Tappino; Paola Ranalli; Lorenza Borin; Luca Facchini; Andrea Patriarca; Wilma Barcellini; Federica Lanza; Mirella Filocamo; Maria Domenica Cappellini
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

9.  Screening for Gaucher Disease Using Dried Blood Spot Tests: A Japanese Multicenter, Cross-sectional Survey.

Authors:  Toshihiro Miyamoto; Masaki Iino; Yasuji Komorizono; Toru Kiguchi; Nobufusa Furukawa; Maki Otsuka; Shohei Sawada; Yutaka Okamoto; Kenji Yamauchi; Toshitaka Muto; Tomoaki Fujisaki; Hisashi Tsurumi; Kimitoshi Nakamura
Journal:  Intern Med       Date:  2021-03-01       Impact factor: 1.271

10.  Scoring system to facilitate diagnosis of Gaucher disease.

Authors:  Atul Mehta; Oliver Rivero-Arias; Magy Abdelwahab; Samantha Campbell; Annabel McMillan; Mark J Rolfe; Jeremy R Bright; David J Kuter
Journal:  Intern Med J       Date:  2020-12       Impact factor: 2.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.